BrightSpring Health Services, Inc.

As of October 17, 2025, BrightSpring Health Services, Inc. is considered undervalued with a P/E ratio of 37, a PEG ratio of 0.12 indicating strong growth potential, and a year-to-date return of 74.57%, outperforming the S&P 500's 13.30%.

As of October 17, 2025, BrightSpring Health Services, Inc. is considered undervalued with an attractive valuation grade, supported by a P/E ratio of 37, a PEG ratio of 0.12, and strong performance, significantly outperforming the S&P 500.

As of September 3, 2025, BrightSpring Health Services, Inc. shows a bullish technical trend with strong momentum indicators, despite a mildly bearish weekly KST, and has significantly outperformed the S&P 500 over the past year.

As of August 5, 2025, BrightSpring Health Services, Inc. is considered undervalued with a favorable valuation grade shift, showing strong performance with a year-to-date return of 60.01% and a one-year return of 83.25%, alongside competitive P/E and EV to EBITDA ratios compared to its peers.

As of May 2, 2025, BrightSpring Health Services, Inc. is considered overvalued with a P/E ratio of 37 and an EV to EBITDA of 12.65, indicating a shift to an expensive valuation grade compared to industry peers, despite a strong year-to-date stock performance of 33.71%.

As of June 6, 2025, the technical trend is bullish with moderate strength, supported by bullish MACD, Bollinger Bands, and moving averages, though a mildly bearish signal from Dow Theory and lack of RSI and KST signals suggest caution.

BrightSpring Health Services, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $2.878 billion and a net profit of $9 million. Key metrics include a market cap of $3.75 billion, a P/E ratio of 37.00, and a debt-to-equity ratio of 1.50.

As of Jun 18, BrightSpring Health Services, Inc. has a market capitalization of $3.75 billion, with recent net sales of $11.57 billion and a net profit of $35.08 million.